Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №10 (2024) > Personalization of therapy in patients with atrial fibrillation: a case report

Personalization of therapy in patients with atrial fibrillation: a case report

O.D. Ostroumova , A.I. Kochetkov , S.V. Litvinova , T.V. Filippova

For citation:


  • Abstract
  • About the Author
  • References

Abstract

A clinical case of a 65-year-old man with newly diagnosed AF is presented. The patient consulted a cardiologist because of a first-time paroxysm of atrial fibrillation (AF), which was stopped with medication in hospital (propafenone at a dose of 1.5 mg/kg intravenously for 10 minutes). It is known from the anamnesis that the patient suffers from arterial hypertension and stage I obesity, and previously suffered from gastric bleeding. According to esophagogastroduodenoscopy, chronic Helicobacter erosive active severe gastritis was detected. During the consultation, the patient was recommended anticoagulant therapy (apixaban 5 mg × 2 times a day), gastroenteroprotective therapy (rebamipide 100 mg × 3 times a day + rabeprazole 20 mg 2 times a day), antiarrhythmic therapy (propafenone 150 mg × 3 times) and H. pylori eradication therapy (clarithromycin 500 mg × 2 times a day, amoxicillin 1000 mg × 2 times a day). Using a specific clinical case as an example, the article discusses modern approaches to improving the safety of anticoagulant therapy and choosing a rhythm control strategy in patients with AF.
Keywords: atrial fibrillation, direct oral anticoagulants, gastroprotective therapy, gastrointestinal bleeding, proton pump inhibitors, rebamipide, antiarrhythmic therapy, antiarrhythmic drugs, propafenone.

About the Author

O.D. Ostroumova 1 , A.I. Kochetkov 2 , S.V. Litvinova 2 , T.V. Filippova 2

1 Russian Medical Academy of Continuous Professional Education, Moscow, Russia; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

2 Russian Medical Academy of Continuous Professional Education, Moscow, Russia

References

1. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Рос. кардиол. журн. 2021;26(7):4594. Arakelyan MG, Bockeria LA, Vasilieva EYu et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian J of Cardiol. 2021;26(7):4594 (in Russian).
2. Li C, Lin C, Lin Y et al. Newly Diagnosed Atrial Fibril- lation Is an Independent Factor for Future Major Adverse Cardiovascular Events. PLoS ONE 2015; 10(4):e0123211.
3. Andersson T, Magnuson A, Bryngelsson I. et al. All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case–control study. Eur Heart J 2013;34(14):1061-1067.
4. Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol. 2017 Mar 21;23(11):1954-1963.
5. Rush KL, Seaton CL, Burton L. et al. Quality of life among patients with atrial fibrillation: A theoretically-guided cross-sectional study. PLoS One. 2023 Oct 5;18(10):e0291575.
6. Aliot E, Botto GL, Crijns HJ, Kirchhof P. Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. Europace. 2014 Jun;16(6):787-796.
7. Консенсус экспертов по снижению риска желудочно-кишечных кровотечений у пациентов, получающих оральные антикоагулянты. Терапия. 2021;10:23-41. Experts consensus on reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants. Therapy. 2021; 10: 23-41 (in Russian).
8. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000 Nov 11;321(7270):1183-1187.
9. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ETTL. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013 Jul;145(1):105-112.e15.
10. Lanas A, García-Rodríguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006 Dec;55(12):1731-1738.
11. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ETTL. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013 Jul;145(1):105-112.e15.
12. Остроумова О.Д., Орлова И.Ю., Кочетков А.И. и др. Структура сопутствующих заболеваний органов пищеварения у пациентов, получающих прямые оральные антикоагулянты: результаты многоцентрового кросс-секционного фармакоэпидемиологического исследования. Терапия. 2022;8(10):152-161. Ostroumova OD, Orlova IY, Kochetkov AI et al. Structure of polymorbidities of the digestive diseases in patients receiving direct oral anticoagulants: results of a multicenter cross-sectional pharmacoepidemiological study. Therapy. 2022;8(10):152-161 (in Russian).
13. Остроумова О.Д., Орлова И.Ю., Кочетков А.И. и др. Структура назначения лекарственных препаратов гастропротективного действия у пациентов, получающих прямые оральные антикоагулянты: результаты многоцентрового кросс-секционного фармакоэпидемиологического исследования. Фарматека. 2022;(13):62-69. Ostroumova OD, Orlova IY, Kochetkov AI et al. Pattern of prescribing gastroprotective drugs in patients receiving direct oral anticoagulants: results of a multicenter cross-sectional pharmacoepidemiological study. Pharmateka. 2022;(13):62-69 (in Russian).
14. Ray WA, Chung CP, Murray KT. et al. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. JAMA 2018 Dec 4;320(21):2221-2230.
15. Daniell HW. NSAID-PPI enteropathy in humans. Gastroenterology. 2012 Apr;142(4):e20; author reply e20-21.
16. Marlicz W, Loniewski I, Grimes DS, Quigley EM. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc 2014;89(12):1699-1709.
17. Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol 2017;23(11):1954–1963.
18. Fawzy AM, Yang WY, Lip GY. Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management. Expert Opin Drug Saf 2019 Mar;18(3):187-209.
19. Gao F, Chen X, Zhang J. Prevalence of Gastric and Small-Intestinal Mucosal Injury in Elderly Patients Taking Enteric-Coated Aspirin by Magnetically Controlled Capsule Endoscopy. Gastroenterol Res Pract 2019 Nov 5;2019:1582590.
20. Tziatzios G, Gkolfakis P, Papanikolaou IS, Triantafyllou K. Antithrombotic Treatment Is Associated with Small-Bowel Video Capsule Endoscopy Positive Findings in Obscure Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. Dig Dis Sci 2019;64(1):15-24.
21. Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. J Pain Res. 2018 Feb 14;11:361-374.
22. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology 2017 Mar;152(4):706-15.
23. Остроумова ОД, Кочетков АИ. Роль нарушений структуры кишечного барьера в патогенезе сердечно-сосудистых заболеваний и возможности ребамипида в их коррекции. Фарматека. 2020;13: 29-41. Ostroumova OD. Kochetkov AI. The role of the disturbances in the intestinal barrier structure in relation to cardiovascular diseases pathogenesis and rebamipid potential in their correction. Farmateka. 2020; 13: 29–41 (in Russian).
24. Клинические рекомендации «Гастрит и дуоденит». Минздрав России. Год утверждения 2024. Clinical guidelines «Gastritis and duodenitis». Ministry of Health of Russia. Year of approval 2024 (in Russian).
25. Feng L, Wen MY, Zhu YJ et al. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23(3):e880-893.
26. Puig I, Baylina M, Sánchez-Delgado J et al. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother. 2016;71(10):2740-53.
27. Nyssen OP, Bordin D, Tepes B et al. Hp-EuReg Investigators. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21533 patients. Gut. 2020;70(1):40-54.
28. Бордин Д.С., Эмбутниекс Ю.В., Вологжанина Л.Г. и др. Европейский регистр Helicobacter pylori (Hp-EuReg): как изменилась клиническая практика в России с 2013 по 2018 г. Терапевтический архив. 2019;91(2):16-24. Bordin DS, Embutnieks YuV, Vologzhanina LG et al. European registry Helicobacter pylori (Hp-EuReg): how has clinical practice changed in Russia from 2013 to 2018 years. Terapevticheskii Arkhiv. 2019;91(2):16-24 (in Russian).
29. Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22(4).
30. Wyse DG, Waldo AL, DiMarco JP. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 Dec 5;347(23):1825-1833.
31. Van Gelder IC, Hagens VE, Bosker HA. et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347(23):1834-1840.
32. Corley SD, Epstein AE, DiMarco JP. et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109(12):1509-1513.
33. Kirchhof P, Camm AJ, Goette A. et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med 2020;383(14):1305-1316.
34. Rillig A, Magnussen C, Ozga AK. et al. Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. Circulation 2021;144(11):845-858.
35. Willems S, Borof K, Brandes A. et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J 2022;43(12):1219-1230.
36. Stoschitzky K, Stoschitzky G, Lercher P. et al. Propafenone shows class Ic and class II antiarrhythmic effects. Europace 2016 Apr;18(4):568-71.
37. Тарасов А.В., Косых С.А., Бушуева Е.В. и др. Сравнение эффективности инъекционных форм антиаритмических препаратов пропафенона и амиодарона при проведении фармакологической кардиоверсии пароксизмальной фибрилляции предсердий. Consilium Medicum. 2019;21(1):81-86. Tarasov AV, Kosykh SA, Bushueva EV et al. Comparison of the efficacy of injectable forms of antiarrhythmic drugs propafenone and amiodarone during pharmacological cardioversion of paroxysmal atrial fibrillation. Consilium Medicum. 2019;21(1):81-86 (in Russian).

For citation:Ostroumova O.D., Kochetkov A.I., Litvinova S.V., Filippova T.V. Personalization of therapy in patients with atrial fibrillation: a case report. Clinical review for general practice. 2024; 5 (10): 70–77 (In Russ.). DOI: 10.47407/kr2024.5.10.00498


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru